DK0509019T3 - Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin - Google Patents

Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin

Info

Publication number
DK0509019T3
DK0509019T3 DK91902028T DK91902028T DK0509019T3 DK 0509019 T3 DK0509019 T3 DK 0509019T3 DK 91902028 T DK91902028 T DK 91902028T DK 91902028 T DK91902028 T DK 91902028T DK 0509019 T3 DK0509019 T3 DK 0509019T3
Authority
DK
Denmark
Prior art keywords
dideoxyinosine
treatment
retroviral infections
human retroviral
human
Prior art date
Application number
DK91902028T
Other languages
Danish (da)
English (en)
Inventor
Robert Yarchoan
Samuel Broder
Hiroaki Mitsuya
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK0509019T3 publication Critical patent/DK0509019T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK91902028T 1990-01-03 1991-01-03 Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin DK0509019T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/460,490 US5026687A (en) 1990-01-03 1990-01-03 Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
PCT/US1991/000005 WO1991009605A1 (fr) 1990-01-03 1991-01-03 Traitement des infections humaines a retrovirus par la 2',3'-dideoxynosine

Publications (1)

Publication Number Publication Date
DK0509019T3 true DK0509019T3 (da) 1999-04-19

Family

ID=23828916

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91902028T DK0509019T3 (da) 1990-01-03 1991-01-03 Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin

Country Status (10)

Country Link
US (2) US5026687A (fr)
EP (1) EP0509019B1 (fr)
JP (1) JP2829545B2 (fr)
AT (1) ATE168268T1 (fr)
AU (1) AU643976B2 (fr)
CA (1) CA2072573C (fr)
DE (1) DE69129800T2 (fr)
DK (1) DK0509019T3 (fr)
ES (1) ES2125233T3 (fr)
WO (1) WO1991009605A1 (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
JP2770970B2 (ja) * 1987-04-09 1998-07-02 フアイソンズ・ピーエルシー ペンタミジンを含有する医薬組成物
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
JPH02204489A (ja) * 1989-02-02 1990-08-14 Ajinomoto Co Inc 易溶性２’，３’―ジデオキシイノシン、その製造法及び２’，３’―ジデオキシイノシン水性溶液の製造法
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) * 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
EP0706387B1 (fr) * 1993-05-21 2004-08-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Nouvelle methode de blocage de la replication de virus susceptibles de transcriptase inverse par utilisation d'inhibiteurs de synthese de desoxynucleotides
EP0631783A1 (fr) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Combinaisons antivirales de 2',3'-didéoxy-ribonucléosides avec des dérivés 5-substitués du 6-benzyl-1-éthoxyméthyl-uracile
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US6130036A (en) * 1994-02-18 2000-10-10 University Of Washington Methods and compositions for screening for anti-AIDS drugs
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5962437A (en) * 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US20030180254A1 (en) * 1995-05-26 2003-09-25 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
JP2000507917A (ja) 1995-11-02 2000-06-27 シェーリング コーポレイション 持続的低用量サイトカイン注入治療
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6528098B2 (en) * 1996-10-22 2003-03-04 Advanced Viral Research Corp. Preparation of a therapeutic composition
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6114312A (en) * 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6800616B2 (en) * 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
AU3786299A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Novel serotonin-like 9-substituted hypoxanthine and methods of use
WO2000016625A1 (fr) * 1998-09-23 2000-03-30 University Of Kentucky Research Foundation Compositions medicamenteuses antivirales contenant des sels inorganiques de lithium
ATE281179T1 (de) 1999-08-13 2004-11-15 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2410579C (fr) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Procedes et compositions de traitement des flavivirus et des pestivirus
US6849735B1 (en) * 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
DK1790344T3 (da) 2000-07-07 2011-05-02 Spectrum Pharmaceuticals Inc Fremgangsmåder til behandling af sygdomsfremkaldt perifer neuropati og beslægtede tilstande
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US20040266723A1 (en) * 2000-12-15 2004-12-30 Otto Michael J. Antiviral agents for treatment of Flaviviridae infections
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US6960738B2 (en) * 2001-05-29 2005-11-01 Koninklijke Philips Electronics N.V. Metal-ceramic bond
ES2358187T3 (es) * 2001-07-10 2011-05-06 JOHNSON & JOHNSON RESEARCH PTY LIMITED Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
EP1423976A1 (fr) * 2001-08-31 2004-06-02 Thomson Licensing S.A. Compteur de sequences destine a un flux audio continu
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
BR0307712A (pt) * 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
RS114004A (sr) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, Modifikovani 2'i 3'-nukleozid prolekovi za lečenje flaviridae infekcija
KR20050040912A (ko) * 2002-08-01 2005-05-03 파마셋 인코포레이티드 플라비비리다에 감염 치료용의 비사이클로[4.2.1]노난시스템을 가지는 화합물
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
WO2005009418A2 (fr) 2003-07-25 2005-02-03 Idenix (Cayman) Limited Analogues des nucleosides puriques pour traiter flaviviridae et notamment l'hepatite c
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
JP2008503562A (ja) * 2004-06-23 2008-02-07 イデニクス（ケイマン）リミテツド フラビウイルス科による感染症を治療するための５−アザ−７−デアザプリン誘導体
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP5001842B2 (ja) 2004-09-14 2012-08-15 ギリアド ファーマセット エルエルシー ２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造
CA2611087A1 (fr) * 2005-06-03 2006-12-14 Advanced Viral Research Corp. Procedes offrant des soins palliatifs a base de avr118
EP2007789B1 (fr) 2006-04-11 2015-05-20 Novartis AG Inhibiteurs spirocycliques du VIH/du virus de l'hépatite C
EP2068906B1 (fr) 2006-09-19 2012-08-01 Sungkyunkwan University Foundation for Corporate Collaboration Agent antiviral agissant contre des virus animaux
WO2008106167A1 (fr) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
HRP20110713T1 (hr) 2007-02-28 2011-11-30 Conatus Pharmaceuticals Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0913677A2 (pt) 2008-07-02 2015-12-15 Idenix Pharmaceuticals Inc composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto
CL2009002208A1 (es) * 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
CL2009002207A1 (es) * 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
EP2403860B1 (fr) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Composes phosphothiophene and phosphothiazole comme agent d'inhibiteur polymerase hcv
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011017389A1 (fr) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de l’hépatite c
WO2011063076A1 (fr) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
CN102917585A (zh) 2010-04-01 2013-02-06 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
CA2811799A1 (fr) 2010-10-08 2012-04-12 Novartis Ag Formulations a base de vitamine e, d'inhibiteurs sulfamides de ns3
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
WO2012080050A1 (fr) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Formes solides d'un composé de phénoxybenzènesulfonyle
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012107584A1 (fr) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Procédés de prédiction des résultats d'une infection par le virus de l'hépatite
WO2012154321A1 (fr) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Composés et compositions pharmaceutiques pour le traitement d'infections virales
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
MX2014001355A (es) 2011-08-03 2014-11-21 Cytheris Inmunoterapia contra el vhc.
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
EP2755985B1 (fr) 2011-09-12 2017-11-01 Idenix Pharmaceuticals LLC Composés et compositions pharmaceutiques pour le traitement d'infections virales
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA3131037A1 (fr) 2011-11-30 2013-06-06 Emory University Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
WO2013133927A1 (fr) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Compositions pharmaceutiques de 2'-c-méthyl-guanosine, 5'-[2-[(3-hydroxy-2,2-diméthyl-1-oxopropyl)thio]éthyl n-(phénylméthyl)phosphoramidate]
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
EP2909223B1 (fr) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Composés dinucléotides contre une infection par le vhc
EP2909222B1 (fr) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC Nucléosides 2', 4'-pontés pour l'infection par le vhc
WO2014078436A1 (fr) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. Ester de d-alanine d'analogue de sp-nucléoside
WO2014078427A1 (fr) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. Ester de d-alanine d'analogue de rp-nucléoside
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
EP2981542B1 (fr) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoronucléosides pour le traitement du vhc
EP3004130B1 (fr) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
EP3046924A1 (fr) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2015061683A1 (fr) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
WO2015066370A1 (fr) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015095419A1 (fr) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. Nucléosides 4'-or pour le traitement du vhc
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (fr) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
EP3448392A4 (fr) 2016-04-28 2020-01-15 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
WO2020185676A1 (fr) * 2019-03-08 2020-09-17 University Of Virginia Patent Foundation Compositions et méthodes de traitement ou de prévention de la maladie d'alzheimer
KR102456699B1 (ko) * 2020-11-19 2022-10-19 주식회사 오에이티씨 디다노신을 포함하는 신경염증성 질환 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
JPS621284A (ja) * 1985-03-28 1987-01-07 Masayoshi Umeno 高速応答性可視発光ダイオ−ド
HU196607B (en) * 1985-05-15 1988-12-28 Wellcome Found Process for producing dideoxy-nucleosides and pharmaceutics comprising such compounds
AU570853B2 (en) * 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US4704357A (en) * 1985-09-30 1987-11-03 United States Of America As Represented By The Department Of Health And Human Services Immortalized T-lymphocyte cell line for testing HTLV-III inactivation
CA1327000C (fr) * 1987-08-07 1994-02-15 David L.J. Tyrrell Therapie antivirale pour l'hepatite b
EP0312222B1 (fr) * 1987-10-14 1992-08-05 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Traitement de maladies virales
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds

Also Published As

Publication number Publication date
ES2125233T3 (es) 1999-03-01
US5376642A (en) 1994-12-27
AU643976B2 (en) 1993-12-02
JPH05506007A (ja) 1993-09-02
JP2829545B2 (ja) 1998-11-25
DE69129800T2 (de) 1999-09-23
AU7175791A (en) 1991-07-24
EP0509019A1 (fr) 1992-10-21
EP0509019A4 (en) 1993-03-24
WO1991009605A1 (fr) 1991-07-11
CA2072573C (fr) 1996-05-28
ATE168268T1 (de) 1998-08-15
DE69129800D1 (de) 1998-08-20
US5026687A (en) 1991-06-25
EP0509019B1 (fr) 1998-07-15
CA2072573A1 (fr) 1991-07-04

Similar Documents

Publication Publication Date Title
DK0509019T3 (da) Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin
NO893400D0 (no) Hiv protease inhibitorer egnet for behandling av aids.
DK198791A (da) Terapeutiske kombinationer af 3'-azido-3'-desoxythymidin og andre terapeutiske midler
FI955315L (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS'n hoitoon
DK524788A (da) Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande
NO911600L (no) Fremgangsmaate for fremstilling av n-(3-fluor-2-fosfonyl-metoksypropyl)-derivater av heterocykliske purin- og pyrimidinbaser.
FI923357A0 (fi) Framstaellning av fettsyramediciner.
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
FI851261A0 (fi) Substituerade bensopyraner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
NO890046L (no) Disubstituerte pyridiner.
UA27713C2 (uk) Амідинові похідні бензолу, що мають гіпоглікемічну активність, та їх фармацевтично прийнятні солі
NO892505D0 (no) Behandling av vandige dispersjoner.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
DK101197A (da) Medikament til behandling af thrombocytopenia
NO881768L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
DK435089A (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
DK0393530T3 (da) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-oner og -thioner og deres anvendelse til forebyggelse eller behandling af AIDS
NO890245L (no) Isoxazoler med nootrop aktivitet.
NO960551D0 (no) Antistoff basert behandling av HIV infeksjon
MX9403275A (es) Metilendioxi[3,'4':6,7]indolizino-[1,2-b]quinolinonas substituidas.
FR2657742B1 (fr) Programmateur-compteur d'unites telephoniques.
KR900007413A (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
NO900044L (no) Hemorroidale, andre blandinger og metoder for behandling.